Heme Biotech changes name to Zymenex and appoints new chairman  

The Hillerød based biopharmaceutical company has changed its name to Zymenex and strengthened its board of directors with Fredric D. Price as new chairman

Heme Biotech has changed its name to Zymenex and strengthened its board of directors to meet its objective of developing and commercialising novel therapeutics for life-threatening diseases. Fredric D. Price, former chairman of the board of directors and CEO of BioMarin Pharmaceutical, California, from October 2000 to August 2004, is the new chairman of Zymenex.


Fredric D. Price says Zymenex could have 3 products on the market during the next 5 years, and could also be stock exchange listed in the same period. Zymenex develops enzyme based niche products for the hospital sector, and has one product currently in Phase 2 development. During the next 18 months, up to 3 other drugs are planned to start human clinical trials.


Zymenex was founded in 1998 and is headquartered in Hillerød, north of Copenhagen, a part of Medicon Valley. The company has laboratory and production facilities in Skovlunde close to Copenhagen, and R&D facilities in Stockholm, Sweden. Zymenex has received investments of DKK 360 mn (USD 64.8). The news is reported by daily financial newspaper Børsen.


Link > Zymenex 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×